EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Anti-vascular endothelial growth factors in retinal and choroidal diseases – Present landscape

Naresh B Kannan, Muthukrishnan Vallinayagam, Konduru Rishitha, Kim Ramasamy

Indian Journal of Ophthalmology · 2026-05 · 74 (5) · 724-734

DOI: 10.4103/ijo.ijo_3149_25 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Indian Journal of Ophthalmology, online erschienen am 29.04.2026. Verfasst von Naresh B Kannan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Retinal Diseases, Choroid Diseases. Die Arbeit nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti-vascular endothelial growth factors (anti-VEGFs) are agents that block the activity of specific bio-active molecules responsible for the growth of abnormal blood vessels. The advent of anti-VEGF therapy has revolutionized the treatment of retinal diseases. They are commonly indicated for diabetic macular edema, choroidal neovascular membrane, cystoid macular edema due to retinal vein occlusion, neovascular glaucoma, and retinopathy of prematurity. The commonly available anti-VEGF agents are bevacizumab, ranibizumab, aflibercept, brolucizumab, and faricimab. The currently practiced treatment regimens include fixed dosing, pro-re-nata, and treat-and-extend. Additionally, biosimilars represent a pivotal shift, offering cost-effective alternatives without compromising therapeutic value. Studies on sustained release anti-VEGF medications like port delivery systems and biodegradable depots are yielding promising outcomes. Ongoing studies analyze the long-term effects of anti-VEGF therapy, aiming to develop next-generation agents with greater durability, efficacy, and safety. This further reduces the treatment burden and offers an extra edge in optimizing long-term visual outcomes. This article provides a comprehensive overview of anti-VEGF therapies including their mechanism of action, efficacy and safety profiles, and landmark trials that have shaped their use in clinical practice. This was a narrative review of the literature that was conducted using PubMed, MEDLINE, Scopus Cochrane library databases, and Google Scholar databases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARetinal DiseasesChoroid DiseasesHumansIntravitreal InjectionsReceptors, Vascular Endothelial Growth FactorRanibizumab

Stichwörter der Autor:innen

AngiogenesisVEGFchoroidal neovascular membraneclinical trialsdiabetic macular edema

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor AReceptors, Vascular Endothelial Growth FactorRanibizumab

Autor:innen und Institutionen

  • Retina and Vitreous Services, Aravind Eye Hospital, Madurai, Tamil Nadu, India.

Zitieren

APA

Kannan, N. B., Vallinayagam, M., Rishitha, K., & Ramasamy, K. (2026). Anti-vascular endothelial growth factors in retinal and choroidal diseases – Present landscape. Indian Journal of Ophthalmology, 74(5), 724-734. https://doi.org/10.4103/ijo.ijo_3149_25

Vancouver

Kannan NB, Vallinayagam M, Rishitha K, Ramasamy K. Anti-vascular endothelial growth factors in retinal and choroidal diseases – Present landscape. Indian Journal of Ophthalmology. 2026;74(5):724-734. doi:10.4103/ijo.ijo_3149_25

BibTeX
@article{Kannan2026,
  author = {Kannan, Naresh B and Vallinayagam, Muthukrishnan and Rishitha, Konduru and Ramasamy, Kim},
  title = {Anti-vascular endothelial growth factors in retinal and choroidal diseases – Present landscape},
  journal = {Indian Journal of Ophthalmology},
  year = {2026},
  volume = {74},
  number = {5},
  pages = {724--734},
  doi = {10.4103/ijo.ijo_3149_25}
}
Kostenlos starten →